|Articles|August 10, 2022
- Pharmaceutical Executive-08-01-2022
- Volume 42
- Issue 8
Pharmaceutical Executive, August 2022 Issue (PDF)
Advertisement
Articles in this issue
almost 4 years ago
The Silver Lining Of Innovation in Genetic Medicinealmost 4 years ago
Navigating the Financial Meltdown for Biopharmaalmost 4 years ago
A Cross-Functional Formula: Operationalizing the Broader Role of Accessalmost 4 years ago
The Potential of Proteomicsalmost 4 years ago
Getting ‘Personal’ With Vaccine Developmentalmost 4 years ago
The Price of Innovation: ‘Paying for a Cure’ Remains Costly Propositionalmost 4 years ago
Milestones and Momentum: Assessing Advancements in Personalized Medicinealmost 4 years ago
A World of Opportunityalmost 4 years ago
Has Biotech Bottomed Out—and is Recent Recovery Sustainable?Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
2
Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
3
FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer
4
Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics
5